Peptide Blood Testing Guide

What blood tests to order before and during peptide research — IGF-1, fasting glucose, HbA1c, liver enzymes, hormones, and how to interpret changes for different peptide classes.

Why Blood Testing Matters

Blood testing provides objective data on how peptide protocols affect the body's biochemistry. Without baseline and follow-up labs, it is impossible to distinguish expected pharmacological effects from concerning adverse changes. Regular monitoring is considered a standard component of responsible peptide research.

Core Panels

IGF-1 (Insulin-Like Growth Factor 1)

Relevance: Primary downstream marker of growth hormone activity. Essential for anyone researching GH secretagogues (Ipamorelin, GHRP-2, GHRP-6, MK-677, Sermorelin, CJC-1295).

Normal adult range: Approximately 100–300 ng/mL (age-dependent; declines ~14% per decade after age 30)
Expected change with GH secretagogues: 20–80% increase from baseline
Concerning findings: IGF-1 above 350–400 ng/mL may warrant dose reduction; persistently elevated levels above the age-adjusted reference range require evaluation Clemmons, 2004

Timing: Draw IGF-1 at least 24 hours after last peptide administration. IGF-1 reflects integrated GH secretion over the preceding 24–48 hours, making it more reliable than a single GH measurement.

Fasting Glucose and HbA1c

Relevance: GH and GH secretagogues are counter-regulatory to insulin, meaning they can impair glucose metabolism. MK-677 in particular has been shown to elevate fasting glucose in clinical studies Nass et al., 2008.

Marker	Normal Range	Action Threshold
Fasting glucose	70–99 mg/dL	>100 mg/dL: monitor closely; >126 mg/dL: concern
HbA1c	<5.7%	>5.7%: pre-diabetic range; re-evaluate protocol
Fasting insulin	2–25 μIU/mL	Trending upward: insulin resistance developing

Expected changes: Mild fasting glucose elevation (5–15 mg/dL) is common with GH secretagogues
When to be concerned: Progressive glucose elevation, HbA1c moving into pre-diabetic range, or fasting insulin rising significantly

Complete Metabolic Panel (CMP)

A comprehensive metabolic panel captures electrolytes, kidney function, and liver function in a single draw.

Key components to watch:

BUN/Creatinine: Kidney function markers; most peptides are renally cleared
eGFR: Estimated glomerular filtration rate; reduced values may alter peptide clearance
Sodium/Potassium: Electrolyte balance; relevant for peptides affecting fluid retention

Liver Enzymes (ALT/AST)

Relevance: Hepatic metabolism is involved in clearance of some peptides and their metabolites. Baseline liver function establishes a reference point.

ALT (alanine aminotransferase): Normal <40 U/L; more specific to liver
AST (aspartate aminotransferase): Normal <40 U/L; also elevated with muscle damage
Expected changes: Most peptides do not significantly impact liver enzymes. Elevations warrant investigation for other causes
Note: Intense exercise (common among peptide researchers) can transiently elevate AST; always interpret in context

Cortisol and Prolactin

Relevance: Some GH secretagogues — particularly GHRP-2 and GHRP-6 — can elevate cortisol and prolactin due to their activation of pathways beyond the GHS-R1a receptor Bowers et al., 1991.

Morning cortisol: Normal 6–23 μg/dL (draw before 9 AM)
Prolactin: Normal <20 ng/mL (males), <25 ng/mL (females)
Ipamorelin is notably selective and does not significantly elevate either marker, which is a key advantage over other GHRPs Raun et al., 1998

Thyroid Panel

Relevance: GH and IGF-1 interact with thyroid hormone metabolism. GH increases conversion of T4 to T3, which can unmask subclinical hypothyroidism or alter thyroid hormone balance during GH secretagogue research.

TSH: Normal 0.4–4.0 mIU/L
Free T4: Normal 0.8–1.8 ng/dL
Free T3: Normal 2.3–4.2 pg/mL
Expected changes: Mild increase in T3 with GH secretagogue use; stable TSH unless pre-existing thyroid condition is present

Reproductive Hormones (LH/FSH)

Relevance: Primarily important when researching peptides that affect the hypothalamic-pituitary-gonadal axis. Melanocortin peptides like PT-141 and Melanotan II may have indirect effects on reproductive hormone signaling.

LH/FSH: Baseline assessment recommended before protocols involving reproductive-pathway peptides
Testosterone/Estradiol: Monitor if combining peptides with other hormonal interventions

Complete Blood Count (CBC)

A general health marker that establishes baseline hematological status.

Hemoglobin/Hematocrit: GH can stimulate erythropoiesis; mild increases may occur
WBC differential: Useful baseline for immune-modulating peptides (Thymalin, Thymosin Alpha-1)
Platelet count: No significant peptide-related changes expected under normal circumstances

Testing Schedule

Timepoint	Tests	Purpose
Baseline (pre-protocol)	IGF-1, CMP, CBC, HbA1c, fasting glucose, fasting insulin, cortisol, prolactin, thyroid panel, LH/FSH (if applicable)	Establish reference values
4 weeks	IGF-1, fasting glucose, fasting insulin	Assess early response; catch glucose issues
8 weeks	IGF-1, CMP, fasting glucose, HbA1c, cortisol, prolactin	Mid-protocol comprehensive check
12 weeks / end of cycle	Full baseline panel repeat	End-of-cycle assessment
4 weeks post-cycle	IGF-1, fasting glucose, HbA1c	Confirm return to baseline

Interpreting Results: Expected vs. Concerning

Expected Changes (Generally Not Alarming)

IGF-1 increase of 20–80% from baseline on GH secretagogues
Mild fasting glucose elevation (5–15 mg/dL) on MK-677 or GHRPs
Mild increase in Free T3 with stable TSH
Transient water retention reflected in mild electrolyte shifts
Slight hemoglobin increase (GH effect on erythropoiesis)

Concerning Changes (Warrant Protocol Review)

IGF-1 >400 ng/mL or more than double baseline
Fasting glucose >126 mg/dL or HbA1c >5.7%
Cortisol consistently elevated above reference range
Prolactin >2x upper normal (rule out pituitary causes)
ALT/AST >2x upper normal (investigate hepatic causes)
Significant creatinine elevation (evaluate renal function)

Context Is Everything

Individual variability is significant. Age, body composition, exercise intensity, diet, sleep quality, and concurrent medications all influence blood markers. A single out-of-range value should be re-tested and confirmed before making protocol changes. Trends over time are more meaningful than isolated readings.